

Andreas Melidonis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7422748/publications.pdf>

Version: 2024-02-01

28
papers

542
citations

1307594

7
h-index

642732

23
g-index

28
all docs

28
docs citations

28
times ranked

925
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes. <i>Current Pharmaceutical Design</i> , 2021, 27, 1035-1042.	1.9	7
2	Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study. <i>Diabetes Therapy</i> , 2020, 11, 2887-2908.	2.5	3
3	Prevalence and correlates of sleep disorders in Greek patients with type 2 diabetes: comparison of an urban and a semi-urban population. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2020, 5, 198-199.	1.0	0
4	Twenty-year trends in the prescription costs of Type 2 diabetes: Real world data and empirical analysis in Greece. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108095.	2.8	1
5	Profile and factors associated with glycaemic control of patients with type 2 diabetes in Greece: results from the diabetes registry. <i>BMC Endocrine Disorders</i> , 2020, 20, 16.	2.2	5
6	Prevalence of erectile dysfunction among Greek men with type 2 diabetes mellitus. <i>Annals of African Medicine</i> , 2020, 19, 73.	0.5	1
7	The influence of gene polymorphisms on postprandial triglyceride response after oral fat tolerance test meal in patients with diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2019, 73, e13432.	1.7	1
8	Effect of 3-month α -lipoic acid treatment on sural nerve conduction velocity and amplitude in patients with diabetic neuropathy: a pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2019, 4, 141-143.	1.0	2
9	Influence of Supervised Disease Understanding and Diabetes Self-Management on Adherence to Oral Glucose-Lowering Treatment in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 1407-1422.	2.5	7
10	Augmentation index as an early marker of in-hospital mortality in patients with acute ischemic stroke. <i>Pan African Medical Journal</i> , 2019, 34, 171.	0.8	1
11	Prediabetes and Atherosclerotic Disease. <i>Angiology</i> , 2019, 70, 101-102.	1.8	2
12	Anti-diabetic treatment leads to changes in gut microbiome. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 688-699.	3.0	16
13	The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2018, 126, 53-60.	1.2	12
14	Circulating microRNAs as biomarkers for diabetic neuropathy: A novel approach. <i>World Journal of Experimental Medicine</i> , 2018, 8, 18-23.	1.7	20
15	Effects of antidiabetic drugs on epicardial fat. <i>World Journal of Diabetes</i> , 2018, 9, 141-148.	3.5	15
16	Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2018, 16, 385-392.	1.7	5
17	Type 2 diabetes and quality of life. <i>World Journal of Diabetes</i> , 2017, 8, 120.	3.5	374
18	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , 2016, 15, 8-14.	1.9	28

#	ARTICLE	IF	CITATIONS
19	A Palpable Painless Axillary Mass as the Clinical Manifestation of Castleman's Disease in a Patient with Hepatitis C Disease. <i>Case Reports in Medicine</i> , 2016, 2016, 1-4.	0.7	1
20	Predictors of left ventricular diastolic dysfunction in type 2 diabetes patients: A 4-year prospective study. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 457-458.	1.0	3
21	Splenic infarcts as a rare manifestation of parvovirus B19 infection. <i>IDCases</i> , 2016, 4, 62-64.	0.9	8
22	The Impact of Continuous Subcutaneous Insulin Infusion Therapy on Efficacy and Safety in a Cohort of Type 1 Diabetes Patients: A 3-Year Prospective Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 159-163.	4.4	3
23	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , 2016, 15, 8-14.	1.9	7
24	Endothelial progenitor cells as a cardiometabolic risk factor marker in prediabetes. <i>Hormones</i> , 2014, 13, 244-251.	1.9	7
25	Head-to-head comparison of 2 inflammatory biomarkers for the long-term prediction of left ventricular diastolic dysfunction in type 2 diabetes patients: Soluble ST2 versus hs-CRP. <i>International Journal of Cardiology</i> , 2014, 174, 811-812.	1.7	7
26	Acute Steatohepatitis, Due to Extreme Metabolic Dysregulation, as the First Presentation of Non-Alcoholic Fatty Liver Disease. <i>Clinics and Practice</i> , 2013, 3, 43-45.	1.4	1
27	Linking Pre-Diabetes with Benign Prostate Hyperplasia. IGFBP-3: A Conductor of Benign Prostate Hyperplasia Development Orchestra?. <i>PLoS ONE</i> , 2013, 8, e81411.	2.5	5
28	No effect of diabetes on intramyocellular diglyceride accumulation in human skeletal muscle. <i>FASEB Journal</i> , 2009, 23, 990.10.	0.5	0